DK1802749T3 - KASPP (LRRK2)-gen, dets fremstilling og anvendelse til påvisning og behandling af neurodegenerative lidelser - Google Patents
KASPP (LRRK2)-gen, dets fremstilling og anvendelse til påvisning og behandling af neurodegenerative lidelserInfo
- Publication number
- DK1802749T3 DK1802749T3 DK05797320.8T DK05797320T DK1802749T3 DK 1802749 T3 DK1802749 T3 DK 1802749T3 DK 05797320 T DK05797320 T DK 05797320T DK 1802749 T3 DK1802749 T3 DK 1802749T3
- Authority
- DK
- Denmark
- Prior art keywords
- kaspp
- lrrk2
- gene
- preparation
- detection
- Prior art date
Links
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 title 1
- 102000009784 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Human genes 0.000 title 1
- 238000001514 detection method Methods 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62089304P | 2004-10-21 | 2004-10-21 | |
| US62116904P | 2004-10-22 | 2004-10-22 | |
| PCT/EP2005/010428 WO2006045392A2 (en) | 2004-10-21 | 2005-09-27 | Kaspp (lrrke) gene, its production and use for the detection and treatment of neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1802749T3 true DK1802749T3 (da) | 2012-11-26 |
Family
ID=35965998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05797320.8T DK1802749T3 (da) | 2004-10-21 | 2005-09-27 | KASPP (LRRK2)-gen, dets fremstilling og anvendelse til påvisning og behandling af neurodegenerative lidelser |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8029986B2 (da) |
| EP (2) | EP1802749B1 (da) |
| AU (1) | AU2005299089B2 (da) |
| CA (1) | CA2584489C (da) |
| DK (1) | DK1802749T3 (da) |
| ES (1) | ES2393926T3 (da) |
| WO (1) | WO2006045392A2 (da) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO323175B1 (no) | 2004-12-23 | 2007-01-15 | Jan O Aasly | Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme |
| MX2008016524A (es) * | 2006-06-20 | 2009-03-09 | Novartis Ag | Biomarcadores para la progresion de la enfermedad de alzheimer. |
| US8206942B2 (en) * | 2007-04-05 | 2012-06-26 | Medical Research Council | Methods of identifying LRRK2 inhibitors |
| US20100186098A1 (en) * | 2007-06-27 | 2010-07-22 | Cornell University | Transgenic animal models of parkinson's disease |
| WO2010020642A1 (en) * | 2008-08-20 | 2010-02-25 | Brainco Biopharma, S.L. | Stxbp1 as psychiatric biomarker in murine model system and their uses |
| US20100175140A1 (en) * | 2008-12-19 | 2010-07-08 | The Johns Hopkins University | Leucine-rich repeat kinase (LRRK2) drosophila model for parkinson's disease: wildtype1 (WT1) and G2019S mutant flies |
| EP2611772B1 (en) | 2010-09-02 | 2014-09-24 | GlaxoSmithKline Intellectual Property Development Limited | 2-(benzyloxy)benzamides as lrrk2 kinase inhibitors |
| PT2760453T (pt) | 2011-09-30 | 2016-08-02 | Ipsen Pharma Sas | Inibidores macrocíclicos da cinase lrrk2 |
| AU2013282869B2 (en) | 2012-06-29 | 2015-12-24 | Pfizer Inc. | Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors |
| WO2015092592A1 (en) | 2013-12-17 | 2015-06-25 | Pfizer Inc. | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| EA029774B1 (ru) | 2014-01-29 | 2018-05-31 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Соединения |
| US10058559B2 (en) | 2014-05-15 | 2018-08-28 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Treatment or prevention of an intestinal disease or disorder |
| WO2016007540A2 (en) | 2014-07-10 | 2016-01-14 | The J. David Gladstone Institutes | Compositions and methods for treating dengue virus infection |
| EA032838B1 (ru) | 2014-09-17 | 2019-07-31 | Онкодизайн С.А. | Макроциклические ингибиторы lrrk2-киназы |
| RU2722149C1 (ru) | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 |
| EP3400300A4 (en) | 2016-01-05 | 2019-08-07 | Ionis Pharmaceuticals, Inc. | PROCESS FOR REDUCING LRRK2 EXPRESSION |
| WO2019012093A1 (en) | 2017-07-14 | 2019-01-17 | Glaxosmithkline Intellectual Property Development Limited | INHIBITORS OF REACTION KINASE 2 RICH IN LEUCINE |
| TWI833770B (zh) | 2018-06-27 | 2024-03-01 | 美商Ionis製藥公司 | 用於減少 lrrk2 表現之化合物及方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| ATE258596T1 (de) | 1993-07-10 | 2004-02-15 | Biognostik Ges | Antigens-nukleinsäure enthaltende pharmazeutische zusammensetzung zur verbeugung und/oder behandlung von neuronalen verletzungen, entartungen und zellentot, und zur behandlung von neoplasmen |
| US6174670B1 (en) | 1996-06-04 | 2001-01-16 | University Of Utah Research Foundation | Monitoring amplification of DNA during PCR |
| WO2003012065A2 (en) * | 2001-08-02 | 2003-02-13 | Incyte Genomics, Inc. | Kinases and phosphatases |
| WO2003101283A2 (en) | 2002-06-04 | 2003-12-11 | Incyte Corporation | Diagnostics markers for lung cancer |
| WO2004006838A2 (en) * | 2002-07-15 | 2004-01-22 | Sugen, Inc. | Novel kinases |
| WO2004023973A2 (en) | 2002-09-12 | 2004-03-25 | Incyte Corporation | Molecules for diagnostics and therapeutics |
-
2005
- 2005-09-27 DK DK05797320.8T patent/DK1802749T3/da active
- 2005-09-27 CA CA2584489A patent/CA2584489C/en not_active Expired - Fee Related
- 2005-09-27 WO PCT/EP2005/010428 patent/WO2006045392A2/en not_active Ceased
- 2005-09-27 EP EP05797320A patent/EP1802749B1/en not_active Expired - Lifetime
- 2005-09-27 ES ES05797320T patent/ES2393926T3/es not_active Expired - Lifetime
- 2005-09-27 EP EP10014786.7A patent/EP2316927B1/en not_active Expired - Lifetime
- 2005-09-27 US US11/665,875 patent/US8029986B2/en not_active Expired - Fee Related
- 2005-09-27 AU AU2005299089A patent/AU2005299089B2/en not_active Ceased
-
2011
- 2011-08-26 US US13/219,131 patent/US8409809B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2316927A2 (en) | 2011-05-04 |
| EP2316927B1 (en) | 2014-11-05 |
| AU2005299089B2 (en) | 2011-08-18 |
| CA2584489C (en) | 2014-07-22 |
| US20100235933A1 (en) | 2010-09-16 |
| WO2006045392A3 (en) | 2006-08-10 |
| US8409809B2 (en) | 2013-04-02 |
| EP1802749B1 (en) | 2012-08-22 |
| EP2316927A3 (en) | 2011-10-19 |
| US8029986B2 (en) | 2011-10-04 |
| CA2584489A1 (en) | 2006-05-04 |
| WO2006045392A2 (en) | 2006-05-04 |
| AU2005299089A1 (en) | 2006-05-04 |
| ES2393926T3 (es) | 2013-01-02 |
| EP1802749A2 (en) | 2007-07-04 |
| US20120035072A1 (en) | 2012-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1802749T3 (da) | KASPP (LRRK2)-gen, dets fremstilling og anvendelse til påvisning og behandling af neurodegenerative lidelser | |
| DK1663978T3 (da) | Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser | |
| DK1824475T3 (da) | Fremgangsmåde til oprensning af trans-(-)-delta9-tetrahydrocannabinol og trans-(+)-delta9-tetrahydrocannabinol | |
| DK1853271T3 (da) | Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme | |
| DK2878297T3 (da) | Lægemidler til behandling og forebyggelse af fibrotiske sygdomme | |
| DK1805312T3 (da) | Fremgangsmåder og midler til fremstilling af hyaluronan | |
| DK2084151T3 (da) | Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme | |
| DK2120604T3 (da) | Fremgangsmåde til fraktionering af havre, produkter derved opnået, og anvendelser deraf | |
| DK1888033T3 (da) | Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme | |
| DK2101819T3 (da) | Fremgangsmåder, sammensætninger og kits til behandling af smerte og pruritis | |
| DK1828164T3 (da) | Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider | |
| DK1667986T3 (da) | Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf | |
| DK1778668T3 (da) | Fremgangsmåde til fremstilling af dihydropteridion | |
| DK2109602T3 (da) | Tetracyclinderivater til behandling af bakterielle, virale og parasitiske infektioner | |
| DK1740197T3 (da) | Prolyl-endopeptidease (PEP) og glutamin-endoprotease til behandlingen af cøliaki | |
| NO20055686L (no) | Sammensetning, fremgangsmate til fremstilling derav, og anvendelse derav. | |
| DK1888294T3 (da) | Fremgangsmåde til hårdlodning af artikler af rustfrit stål | |
| DK2350093T3 (da) | Substituerede 4,5,6,7-tetrahydrothienopyridiner som KCNQ2/3-modulatorer til behandling af smerte, epilepsi og urininkontinens. | |
| DK1765355T3 (da) | Benzoxazin til behandling af luftvejslidelser | |
| DK1916995T4 (da) | Ph-styret, pulserende indgivelsessystem, fremgangsmåder til fremstilling og anvendelse deraf | |
| DK2422786T3 (da) | Nye lægemiddelkombinationer til behandling af luftvejssygdomme | |
| EP1896625A4 (en) | DEVICE AND METHOD FOR CHECKING THE THICKNESS | |
| DK1848415T3 (da) | Kombinationsterapi med glatirameracetat og rasagilin til behandling af multipel sklerose | |
| DK2617714T3 (da) | Kemiske derivater af jasmonat, farmaceutiske præparater og fremgangsmåder til anvendelse deraf | |
| DK1589973T4 (da) | Formulering og fremgangsmåder til behandling af thrombocytæmi |